타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 5개 · 임상 갱신 필요 5개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | datopotamab deruxtecan-dlnk (Datroway, DS-1062, Dato-DXd) Daiichi Sankyo / AstraZeneca·TROP2 50 trials | telisotuzumab vedotin (Emrelis, ABBV-399, Teliso-V, telisotuzumab-vedotin-tllv) AbbVie·c-Met 12 trials·t½ ADC in the range of days; free MMAE shorter | Platinum Based Chemotherapy (Platinum Based Chemotherapy) Merck Sharp & Dohme LLC·Ovarian Cancer 128 trials | ||
|---|---|---|---|---|---|
Overview Program | Enhertu (fam-trastuzumab deruxtecan-nxki) | Datroway (datopotamab deruxtecan-dlnk) | Tisotumab Vedotin | Emrelis (telisotuzumab vedotin) | Platinum Based Chemotherapy |
Overview Company | Daiichi Sankyo / AstraZeneca | Daiichi Sankyo / AstraZeneca | Genmab / Pfizer | AbbVie | Merck Sharp & Dohme LLC |
Overview Modality | ADC | ADC | ADC | ADC | ADC |
Overview Target | HER2 | TROP2 | Solid Malignancies | c-Met | Ovarian Cancer |
Overview Indication | HER2-positive breast cancer (including regimen-specific first-line and early-stage indications); HER2-low/ultralow breast cancer, HER2-positive gastric cancer, HER2-mutant NSCLC and HER2-positive solid tumors: consult the current US label | HR-positive/HER2-negative breast cancer after specified prior therapies; EGFR-mutated NSCLC after specified prior therapies; first-line TNBC unsuitable for PD-1/PD-L1 therapy. Consult current US label. | Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Previously treated locally advanced or metastatic non-squamous NSCLC with high c-Met protein overexpression | Nonsquamous Non-small Cell Lung Cancer; EGFR L858R |
Overview Phase | APPROVED | APPROVED | APPROVED | APPROVED | PHASE_3 |
Overview Status | APPROVED | APPROVED | APPROVED | APPROVED | RECRUITING |
Overview Content status | Curated Core | Curated Core | Curated Core | Curated Core | Limited Data |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · limited data |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Emerging |
Overview Approval status | FDA approved | FDA approved | FDA approved | FDA approved | Investigational |
Positioning Key differentiator | High DAR (~8), bystander effect, HER2-low activity | Same DXd chemistry that made Enhertu work, aimed at TROP2 — high plasma stability with a short-half-life payload to limit systemic exposure. | — | Selects high c-Met protein overexpression by IHC, not MET gene mutation. That split is the first row versus MET TKIs. | — |
Positioning Known limitation | HER2 antigen loss/downregulation, payload efflux, and dose-limiting ILD/pneumonitis leading to discontinuation. | TROP2 loss, SLFN11 status, and topoisomerase I pathway adaptation. | — | c-Met down-regulation, MMAE efflux, and histologic transformation. | — |
Positioning Development positioning | Indication- and regimen-specific; includes 1L + pertuzumab in HER2-positive metastatic breast cancer | Indication-specific; includes 1L TNBC unsuitable for PD-1/PD-L1 therapy | — | 2L+ | — |
Technology Payload | DXd (topo-I inhibitor) | DXd (exatecan derivative, topoisomerase I inhibitor) | — | MMAE (microtubule inhibitor) | vedotin (ARON-2EV study) |
Technology Linker | Cleavable tetrapeptide | Tetrapeptide-based cleavable maleimide linker, DAR ~4 | — | Cleavable vc linker, vedotin chemistry | — |
Technology DAR | — | DAR 4 | — | — | — |
MoA Mechanism | Fam-trastuzumab deruxtecan is a HER2-directed antibody-drug conjugate: humanized anti-HER2 IgG1 linked via a cleavable tetrapeptide linker to DXd, a membrane-permeable topoisomerase I inhibitor. After binding HER2 on tumor cells, the conjugate is internalized; lysosomal proteases cleave the linker and release DXd, causing DNA damage and apoptosis. Released DXd can exert a bystander effect in neighboring cells. | Anti-TROP2 antibody delivers DXd intracellularly after lysosomal linker cleavage; topoisomerase I inhibition drives DNA damage, with membrane-permeable payload producing a bystander effect. | — | Anti-c-Met antibody binds and internalizes; the protease-cleavable linker releases MMAE, which disrupts microtubules and kills the cell plus neighbors via bystander diffusion. | targeting oxidative stress, hypoxia, persistent DNA damage, immune signaling |
MoA Biomarker | HER2 expression (IHC/ISH per indication); higher systemic exposure associated with greater ILD incidence (FDA label §12.2). | TROP2 expression is not a required companion diagnostic; quantitative continuous scoring (QCS) is investigational. | — | VENTANA MET (SP44) companion diagnostic. High overexpression is ≥50% of cells with 3+ staining, not MET exon 14 skipping. | biomarker-embedded clinical trials, molecular subtype-stratified patient selection, and rigorous evaluation o |
PK/PD Half-life | — | — | — | ADC in the range of days; free MMAE shorter | — |
PK/PD Animal (cat.) | — | — | — | Human | — |
Toxicology Species | Cynomolgus monkey, NHP, Rat, Hamster | Rat, Hamster | — | — | — |
Toxicology Animal (cat.) | NHP | — | — | — | — |
Toxicology Major finding | ILD-like lung findings at high exposure | Stomatitis, dry eye and keratitis, nausea, and alopecia. Interstitial lung disease is a class warning for DXd conjugates and requires prompt steroid intervention. | Pneumonitis: Severe, life-threatening, or fatal pneumonitis may occur | Peripheral neuropathy, fatigue, decreased appetite, and peripheral edema are common. Grade 3–4 lab signals include lymphopenia and transaminase rises. | — |
Toxicology CRS | Minimal | N/A | — | N/A | — |
Toxicology NOAEL | 10 mg/kg | — | — | — | — |
Clinical Safety signal | ILD-like lung findings at high exposure | Stomatitis, dry eye and keratitis, nausea, and alopecia. Interstitial lung disease is a class warning for DXd conjugates and requires prompt steroid intervention. | Pneumonitis: Severe, life-threatening, or fatal pneumonitis may occur | Peripheral neuropathy, fatigue, decreased appetite, and peripheral edema are common. Grade 3–4 lab signals include lymphopenia and transaminase rises. | — |
Clinical Selected reported efficacy | ORR 87% | ORR 64% | — | — | — |
Clinical Reported ORR | 87% vs 81% (THP) | 64% vs 30% (chemotherapy) | — | — | — |
Clinical Reported PFS | 40.7 months vs 26.9 months (THP) | 10.8 months vs 5.6 months (chemotherapy) | — | — | — |
Clinical Reported OS | Immature at the reported PFS analysis | 23.7 months vs 18.7 months (chemotherapy) | — | — | — |
Clinical Result source | FDA label 2026, Table 28 — DESTINY-Breast09 (NCT04784715) | FDA approval report 2026-05-22 — TROPION-Breast02 (NCT05374512) | — | — | — |
Clinical Program phase | APPROVED | APPROVED | APPROVED | APPROVED | PHASE_3 |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts | — | No active/completed counts |
Clinical Trial ref | NCT04784715 | NCT05374512 | — | — | — |
Preclinical Animal (cat.) | Human, Mouse, In vitro | Mouse, In vitro | — | — | — |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 5개 · 임상 갱신 필요 5개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | datopotamab deruxtecan-dlnk (Datroway, DS-1062, Dato-DXd) Daiichi Sankyo / AstraZeneca·TROP2 50 trials | telisotuzumab vedotin (Emrelis, ABBV-399, Teliso-V, telisotuzumab-vedotin-tllv) AbbVie·c-Met 12 trials·t½ ADC in the range of days; free MMAE shorter | Platinum Based Chemotherapy (Platinum Based Chemotherapy) Merck Sharp & Dohme LLC·Ovarian Cancer 128 trials | ||
|---|---|---|---|---|---|
Overview Program | Enhertu (fam-trastuzumab deruxtecan-nxki) | Datroway (datopotamab deruxtecan-dlnk) | Tisotumab Vedotin | Emrelis (telisotuzumab vedotin) | Platinum Based Chemotherapy |
Overview Company | Daiichi Sankyo / AstraZeneca | Daiichi Sankyo / AstraZeneca | Genmab / Pfizer | AbbVie | Merck Sharp & Dohme LLC |
Overview Modality | ADC | ADC | ADC | ADC | ADC |
Overview Target | HER2 | TROP2 | Solid Malignancies | c-Met | Ovarian Cancer |
Overview Indication | HER2-positive breast cancer (including regimen-specific first-line and early-stage indications); HER2-low/ultralow breast cancer, HER2-positive gastric cancer, HER2-mutant NSCLC and HER2-positive solid tumors: consult the current US label | HR-positive/HER2-negative breast cancer after specified prior therapies; EGFR-mutated NSCLC after specified prior therapies; first-line TNBC unsuitable for PD-1/PD-L1 therapy. Consult current US label. | Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Previously treated locally advanced or metastatic non-squamous NSCLC with high c-Met protein overexpression | Nonsquamous Non-small Cell Lung Cancer; EGFR L858R |
Overview Phase | APPROVED | APPROVED | APPROVED | APPROVED | PHASE_3 |
Overview Status | APPROVED | APPROVED | APPROVED | APPROVED | RECRUITING |
Overview Content status | Curated Core | Curated Core | Curated Core | Curated Core | Limited Data |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · limited data |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Emerging |
Overview Approval status | FDA approved | FDA approved | FDA approved | FDA approved | Investigational |
Positioning Key differentiator | High DAR (~8), bystander effect, HER2-low activity | Same DXd chemistry that made Enhertu work, aimed at TROP2 — high plasma stability with a short-half-life payload to limit systemic exposure. | — | Selects high c-Met protein overexpression by IHC, not MET gene mutation. That split is the first row versus MET TKIs. | — |
Positioning Known limitation | HER2 antigen loss/downregulation, payload efflux, and dose-limiting ILD/pneumonitis leading to discontinuation. | TROP2 loss, SLFN11 status, and topoisomerase I pathway adaptation. | — | c-Met down-regulation, MMAE efflux, and histologic transformation. | — |
Positioning Development positioning | Indication- and regimen-specific; includes 1L + pertuzumab in HER2-positive metastatic breast cancer | Indication-specific; includes 1L TNBC unsuitable for PD-1/PD-L1 therapy | — | 2L+ | — |
Technology Payload | DXd (topo-I inhibitor) | DXd (exatecan derivative, topoisomerase I inhibitor) | — | MMAE (microtubule inhibitor) | vedotin (ARON-2EV study) |
Technology Linker | Cleavable tetrapeptide | Tetrapeptide-based cleavable maleimide linker, DAR ~4 | — | Cleavable vc linker, vedotin chemistry | — |
Technology DAR | — | DAR 4 | — | — | — |
MoA Mechanism | Fam-trastuzumab deruxtecan is a HER2-directed antibody-drug conjugate: humanized anti-HER2 IgG1 linked via a cleavable tetrapeptide linker to DXd, a membrane-permeable topoisomerase I inhibitor. After binding HER2 on tumor cells, the conjugate is internalized; lysosomal proteases cleave the linker and release DXd, causing DNA damage and apoptosis. Released DXd can exert a bystander effect in neighboring cells. | Anti-TROP2 antibody delivers DXd intracellularly after lysosomal linker cleavage; topoisomerase I inhibition drives DNA damage, with membrane-permeable payload producing a bystander effect. | — | Anti-c-Met antibody binds and internalizes; the protease-cleavable linker releases MMAE, which disrupts microtubules and kills the cell plus neighbors via bystander diffusion. | targeting oxidative stress, hypoxia, persistent DNA damage, immune signaling |
MoA Biomarker | HER2 expression (IHC/ISH per indication); higher systemic exposure associated with greater ILD incidence (FDA label §12.2). | TROP2 expression is not a required companion diagnostic; quantitative continuous scoring (QCS) is investigational. | — | VENTANA MET (SP44) companion diagnostic. High overexpression is ≥50% of cells with 3+ staining, not MET exon 14 skipping. | biomarker-embedded clinical trials, molecular subtype-stratified patient selection, and rigorous evaluation o |
PK/PD Half-life | — | — | — | ADC in the range of days; free MMAE shorter | — |
PK/PD Animal (cat.) | — | — | — | Human | — |
Toxicology Species | Cynomolgus monkey, NHP, Rat, Hamster | Rat, Hamster | — | — | — |
Toxicology Animal (cat.) | NHP | — | — | — | — |
Toxicology Major finding | ILD-like lung findings at high exposure | Stomatitis, dry eye and keratitis, nausea, and alopecia. Interstitial lung disease is a class warning for DXd conjugates and requires prompt steroid intervention. | Pneumonitis: Severe, life-threatening, or fatal pneumonitis may occur | Peripheral neuropathy, fatigue, decreased appetite, and peripheral edema are common. Grade 3–4 lab signals include lymphopenia and transaminase rises. | — |
Toxicology CRS | Minimal | N/A | — | N/A | — |
Toxicology NOAEL | 10 mg/kg | — | — | — | — |
Clinical Safety signal | ILD-like lung findings at high exposure | Stomatitis, dry eye and keratitis, nausea, and alopecia. Interstitial lung disease is a class warning for DXd conjugates and requires prompt steroid intervention. | Pneumonitis: Severe, life-threatening, or fatal pneumonitis may occur | Peripheral neuropathy, fatigue, decreased appetite, and peripheral edema are common. Grade 3–4 lab signals include lymphopenia and transaminase rises. | — |
Clinical Selected reported efficacy | ORR 87% | ORR 64% | — | — | — |
Clinical Reported ORR | 87% vs 81% (THP) | 64% vs 30% (chemotherapy) | — | — | — |
Clinical Reported PFS | 40.7 months vs 26.9 months (THP) | 10.8 months vs 5.6 months (chemotherapy) | — | — | — |
Clinical Reported OS | Immature at the reported PFS analysis | 23.7 months vs 18.7 months (chemotherapy) | — | — | — |
Clinical Result source | FDA label 2026, Table 28 — DESTINY-Breast09 (NCT04784715) | FDA approval report 2026-05-22 — TROPION-Breast02 (NCT05374512) | — | — | — |
Clinical Program phase | APPROVED | APPROVED | APPROVED | APPROVED | PHASE_3 |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts | — | No active/completed counts |
Clinical Trial ref | NCT04784715 | NCT05374512 | — | — | — |
Preclinical Animal (cat.) | Human, Mouse, In vitro | Mouse, In vitro | — | — | — |
추천 비교
추천 비교